Clinical trials in Rotterdam – page 48

796 clinical trials in Rotterdam, The Netherlands across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Rotterdam at a glance

796

clinical trials

Research sites7

Quick filters

796 trials in Rotterdam

Open in trial search

Triple negative breast cancer

Not recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Obesity

Not recruiting

Study of Setmelanotide for Patients with Obesity Due to Specific Genetic Variants

Registered drug

Study of Setmelanotide for Patients with Obesity Due to Specific Genetic Variants

Registered drug

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Setmelanotide
Sponsor:Rhythm Pharmaceuticals Inc.

Contact Research Centre

Hidradenitis

Not recruiting

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lutikizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Neoplasm

Not recruiting

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

Registered drugNo placebo

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Df1001
Sponsor:Dragonfly Therapeutics Inc.

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Enasidenib Mesilate
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

B precursor type acute leukaemia

Not recruiting

Study on Adding Blinatumomab to Treatment for Adults with Precursor B-Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study on Adding Blinatumomab to Treatment for Adults with Precursor B-Acute Lymphoblastic Leukemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Breast cancer stage III+2

Not recruiting

Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

Registered drugNo placebo

Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Colorectal cancer+1

Not recruiting

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Catharina Ziekenhuis Stichting

Contact Research Centre

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Ovarian cancer

Not recruiting

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Alrefimotide
Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Contact Research Centre

Diffuse large B-cell lymphoma+1

Not recruiting

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo

The Netherlands

Participants:18–64 years
Substances:Brentuximab Vedotin
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Rotterdam

What the registry says about research in the country

01 Neurology and Mental Health

Innovative research focusing on frontotemporal dementia treatments and management of migraine in relation to obesity. Studies include evaluation of new therapeutic compounds and their effects on neurological conditions.

Dementia Treatment Studies
Migraine Management Research
Neurological Disease Interventions

Research aims to improve patient outcomes through targeted therapeutic approaches and innovative treatment methods.

02 Oncology and Cancer Research

Comprehensive studies targeting various forms of cancer, including advanced gastric cancer and bladder cancer. Research includes innovative imaging techniques and combination therapy approaches.

Gastric Cancer Treatment
Cancer Immunotherapy
Diagnostic Imaging Studies

Focus on developing more effective treatment strategies and improving diagnostic capabilities.

03 Metabolic and Endocrine Disorders

Clinical trials addressing obesity and related metabolic conditions, including innovative approaches to weight management and metabolic disease treatment. Studies evaluate new therapeutic options for thyroid disorders.

Weight Management Therapies
Thyroid Disease Treatment
Metabolic Disease Research

Research focuses on developing effective treatments for complex metabolic conditions.

Back to the Netherlands All countries